查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595214

陣發性夜間血尿症治療市場：透過診斷測試、治療 - 全球預測 2025-2030

Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test (Bone Marrow Examination, Complete Blood Count Test, Flow Cytometry), Treatment (Blood Transfusion, Medication, Stem Cell Transplant) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

陣發性夜間血尿症治療市場2023年估值為31.5億美元，預計2024年將達34.9億美元，複合年成長率為10.88%，2030年將達65億美元，預計將達到1000萬美元。

陣發性夜間血尿症(PNH) 是一種罕見的危及生命的疾病，其特徵是紅血球破壞、血栓和骨髓功能受損。 PNH 的治療包括依Eculizumab)和拉維珠單抗 (Ravulizumab)等藥物，這些藥物以補體抑制為目標，以減少溶血並控制症狀。需求在於與 PNH 相關的嚴重併發症，強調需要有效的治療來提高患者的生活品質和存活率。應用範圍從血液學到個人化護理非常重要的專業醫療機構。最終用途包括醫院、臨床研究機構、專科診所等。市場成長在很大程度上受到意識提高、生物醫學研究進步以及新治療方法的可用性的影響。政府對孤兒藥的支持以及生技公司之間的合作正在幫助擴大市場。需求未滿足的地區存在商機，特別是在醫療基礎設施低度開發的地區，這表明市場存在地理和人口擴張的可能性。透過數位醫療平台增強病人參與帶來了進一步的成長機會。然而，它面臨著高昂的治療成本和有限的患者數量以及醫藥品認證過程中的監管障礙的挑戰。此外，對疾病機制的了解有限也限制了創新。然而，市場上的一些研究領域有望簡化治療通訊協定，例如基因治療和更有效的診斷工具。對臨床試驗和研究合作的持續投資可以帶來突破性創新。市場的利基但不斷發展的性質要求相關人員在引入新技術時保持敏捷。投資意識宣傳活動和利用患者的倡導也可以推動參與。透過解決這些動態，公司可以克服 PNH 治療市場固有的複雜性，同時利用擴張機會。

主要市場統計
基準年[2023] 31.5億美元
預測年份 [2024] 34.9億美元
預測年份 [2030] 65.1億美元
複合年成長率（%） 10.88%

市場動態：快速陣發性夜間血尿症治療市場的關鍵市場洞察

供給和需求的動態交互作用正在改變陣發性夜間血尿症治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 新療法的採用增加
    • 人口老化的加劇和生技藥品的興起
    • 血液和骨髓相關疾病增加
  • 市場限制因素
    • 治療高成本
  • 市場機會
    • 增加幹細胞研究和開發
    • 加大PNH治療研發投入
  • 市場挑戰
    • 現有治療方法的副作用

波特五力：駕馭陣發性夜間血尿症治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解陣發性夜間血尿症治療市場的外部影響

外部宏觀環境因素在塑造陣發性夜間血尿症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解陣發性夜間血尿症治療市場的競爭格局

對陣發性夜間血尿症治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣陣發性陣發性夜間血尿症治療市場供應商的績效評估

FPNV定位矩陣是評估陣發性夜間血尿症治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了陣發性夜間血尿症治療市場的成功之路

對陣發性夜間血尿症治療市場的策略分析對於希望加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 增加新治療方法的採用
      • 人口老化的加劇和生物製藥的出現
      • 血液和骨髓相關疾病增加
    • 抑制因素
      • 醫療費用上漲
    • 機會
      • 幹細胞研究進展
      • 加大PNH治療研發投入
    • 任務
      • 現有治療方法的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章陣發性夜間血尿症治療市場診斷測試

  • 骨髓檢查
  • 全血球計數測試
  • 流式細胞技術
  • 乳酸脫氫酵素測試
  • 含鐵血黃素尿液檢查

第7章陣發性夜間血尿症治療市場（依治療）

  • 輸血
  • 藥物治療
  • 幹細胞移植

第8章北美與南美陣發性夜間血尿症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區陣發性夜間血尿症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲陣發性夜間血尿症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Akari Therapeutics, PLC
  • Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Amyndas Pharmaceuticals
  • Apellis Pharmaceuticals, Inc.
  • CinnaGen Co.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Ra Pharma by Cohance Lifesciences
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-036C5CF3B54F

The Paroxysmal Nocturnal Hemoglobinuria Treatment Market was valued at USD 3.15 billion in 2023, expected to reach USD 3.49 billion in 2024, and is projected to grow at a CAGR of 10.88%, to USD 6.51 billion by 2030.

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, life-threatening disease characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function. The scope of PNH treatment involves medications like eculizumab and ravulizumab targeting complement inhibition to reduce hemolysis and manage symptoms. The necessity lies in the severe complications associated with PNH, underscoring the need for effective treatments to improve patients' quality of life and survival rates. Application extends to hematology and specialized healthcare facilities where personalized care is crucial. End-use scope prominently includes hospitals, clinical research institutes, and specialty clinics. Market growth is significantly influenced by increased awareness, advances in biomedical research, and the availability of novel therapies. Government support for orphan drugs and collaborations between biotech firms are aiding market expansion. Opportunities arise in unmet clinical needs, particularly in regions lacking robust healthcare infrastructure, hinting at potential geographic and demographic market expansion. Enhancing patient engagement through digital healthcare platforms presents additional opportunities for growth. However, high treatment costs and limited patient population pose challenges, alongside regulatory hurdles in drug approval processes. Furthermore, the limited understanding of the disease mechanism poses constraints on innovation. Nonetheless, the market presents areas ripe for research, such as genetic therapies and more efficient diagnostic tools, promising to ease treatment protocols. Continued investment in clinical trials and collaborative research could foster breakthrough innovations. The nature of the market is niche yet evolving, requiring stakeholders to maintain agility in adopting emerging technologies. Investment in awareness campaigns and leveraging patient advocacy can also drive engagement. By addressing these dynamics, companies can harness expansion opportunities while navigating the complexities inherent in the PNH treatment market.

KEY MARKET STATISTICS
Base Year [2023] USD 3.15 billion
Estimated Year [2024] USD 3.49 billion
Forecast Year [2030] USD 6.51 billion
CAGR (%) 10.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Paroxysmal Nocturnal Hemoglobinuria Treatment Market

The Paroxysmal Nocturnal Hemoglobinuria Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of novel therapeutics
    • Rising geriatric population and the emergence of biologics
    • Growing number of blood and bone marrow related disorders
  • Market Restraints
    • High costs associated with medical treatment
  • Market Opportunities
    • Increasing development in stem cell research
    • Rising investment in research & development of PNH treatment drugs
  • Market Challenges
    • Adverse side effects with existing treatments

Porter's Five Forces: A Strategic Tool for Navigating the Paroxysmal Nocturnal Hemoglobinuria Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Paroxysmal Nocturnal Hemoglobinuria Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Paroxysmal Nocturnal Hemoglobinuria Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market

A detailed market share analysis in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Paroxysmal Nocturnal Hemoglobinuria Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market

A strategic analysis of the Paroxysmal Nocturnal Hemoglobinuria Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market, highlighting leading vendors and their innovative profiles. These include Akari Therapeutics, PLC, Alexion Pharmaceuticals, Inc. by AstraZeneca PLC, Alnylam Pharmaceuticals, Inc., Amgen Inc., Amyndas Pharmaceuticals, Apellis Pharmaceuticals, Inc., CinnaGen Co., F. Hoffmann-La Roche AG, Novartis AG, Ra Pharma by Cohance Lifesciences, Regeneron Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Paroxysmal Nocturnal Hemoglobinuria Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnostic Test, market is studied across Bone Marrow Examination, Complete Blood Count Test, Flow Cytometry, Lactate Dehydrogenase Test, and Urine Test for Hemosiderin.
  • Based on Treatment, market is studied across Blood Transfusion, Medication, and Stem Cell Transplant.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of novel therapeutics
      • 5.1.1.2. Rising geriatric population and the emergence of biologics
      • 5.1.1.3. Growing number of blood and bone marrow related disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with medical treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing development in stem cell research
      • 5.1.3.2. Rising investment in research & development of PNH treatment drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse side effects with existing treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Diagnostic Test

  • 6.1. Introduction
  • 6.2. Bone Marrow Examination
  • 6.3. Complete Blood Count Test
  • 6.4. Flow Cytometry
  • 6.5. Lactate Dehydrogenase Test
  • 6.6. Urine Test for Hemosiderin

7. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Blood Transfusion
  • 7.3. Medication
  • 7.4. Stem Cell Transplant

8. Americas Paroxysmal Nocturnal Hemoglobinuria Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akari Therapeutics, PLC
  • 2. Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
  • 3. Alnylam Pharmaceuticals, Inc.
  • 4. Amgen Inc.
  • 5. Amyndas Pharmaceuticals
  • 6. Apellis Pharmaceuticals, Inc.
  • 7. CinnaGen Co.
  • 8. F. Hoffmann-La Roche AG
  • 9. Novartis AG
  • 10. Ra Pharma by Cohance Lifesciences
  • 11. Regeneron Pharmaceuticals, Inc.
  • 12. Samsung Bioepis Co., Ltd.
  • 13. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BONE MARROW EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLETE BLOOD COUNT TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LACTATE DEHYDROGENASE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY URINE TEST FOR HEMOSIDERIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023